Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data

Corvus Pharmaceuticals(NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic dermatitis (eczema) showed strong efficacy and clean safety, and investors are watching further development of the eczema program.
Trading volume reached 82 million shares, about 3,032% above its three-month average of 2.6 million shares. Corvus Pharmaceuticals IPO'd in 2016 and has dropped 44% since going public.

How the markets moved today

The S&P 500 fell 2.06% to 6,797, while the Nasdaq Composite lost 2.39% to finish at 22,954. Among biotechnology names, Olema Pharmaceuticals closed at $26.72, up 1.79%, while Ventyx Biosciences ended at $13.88, up 0.14%, as investors gauge drug development pipelines.

What this means for investors

Corvus rocketed higher today after it released Phase 1 soquelitinib data for treating eczema, showing excellent patient responses with no serious adverse events. Management plans to move on to a Phase 2 trial later this quarter. Today’s success, paired with soquelitinib’s potential to help with lymphoma, gives the company an intriguing future for healthcare-savvy investors to monitor.

Following the stock’s rise today, management announced a $150 million share offering, along with pre-funded warrants, to capitalize on the stock’s more than doubled share price. Before today, Corvus Pharmaceutical’s market cap was less than $500 million, so the news is a significant boon for the company. That said, the company is still pre-revenue, so investors should be cautious when buying this biotech as nothing is yet guaranteed.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia:if you invested $1,000 when we doubled down in 2009,you’d have $483,029!* Apple: if you invested $1,000 when we doubled down in 2008, you’d have $48,612!* Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $474,578!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you joinStock Advisor, and there may not be another chance like this anytime soon.

Story Continues

See the 3 stocks »

*Stock Advisor returns as of January 20, 2026

Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data was originally published by The Motley Fool

View Comments